Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Development of cellular resistance to multiple types of anticancer agents has been recognized as one of the major obstacles for the effective cancer chemotherapy. Increased expression of mdr 1 mRNA seems to be a common mechanism for multidrug resistance (MDR) in human malignant cells. The product of the mdr 1 gene is
P-glycoprotein
. The predicted membrane orientation of the protein and homology with bacterial active transport proteins, and capability of the protein to bind hydrophobic anticancer agents are consistent with the function of
P-glycoprotein
as an energy-dependent efflux pump responsible for MDR phenotype. Most of the hydrophobic agents which overcome MDR are cationic and amphipathic. These agents interact with certain polar lipids and inhibit also the binding of hydrophobic anticancer agents with
P-glycoprotein
. They might directly bind to the binding site of anticancer agents on
P-glycoprotein
and competitively inhibit the binding of anticancer agents. Alternatively, they might bind to polar lipids of membrane vesicles and indirectly inhibit the binding ability of the protein to anticancer agents by perturbing the membrane function.
Gan To Kagaku Ryoho 1987
Sep
PMID:[A molecular basis for multidrug-resistance and reversal of resistance with human malignant cells]. 288 34
The Mr 170,000 to 180,000 membrane glycoprotein associated with multidrug resistance (
P-glycoprotein
) is involved in drug transport mechanisms across the plasma membrane of multidrug-resistant cells. We have recently reported the purification of
P-glycoprotein
. The purified
P-glycoprotein
was found to have an ATPase activity, which might be coupled with the active efflux of anticancer drugs. In the present study, we have further studied the properties of the
P-glycoprotein
ATPase activity by an immobilized enzyme assay procedure using a
P-glycoprotein
-antibody-Protein A-Sepharose complex. GTP was also hydrolyzed by the
P-glycoprotein
, although less efficiently than ATP. The ATPase activity of
P-glycoprotein
had an optimal pH range around neutrality (pH 6.5-7.4). The detergent concentration of 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propane sulfonate used for protein solubilization was essential for enzyme recovery. Maximum activity was obtained when 0.1-0.2% 3-[(3-cholamidopropyl)dimethyl-ammonio]-propane sulfonate was used, while higher concentrations markedly inhibited the ATPase activity. The ATPase activity was dependent on Mg2+; maximum activity was obtained at 2-10 mM. Manganese and cobalt could substitute for magnesium as ionic cofactors. Divalent cations such as Ca2+, Zn2+, Ni2+, Cd2+, and Cu2+ inhibited the Mg2+-catalyzed ATP hydrolysis. N-Ethylmaleimide and vanadate inhibited the ATPase activity, while sodium azide or ouabain had no effect. Anticancer agents such as vincristine and Adriamycin did not affect the enzyme activity. In contrast, verapamil and trifluoperazine, agents which inhibit active drug efflux and restore drug sensitivity in resistant cells, caused an increase in the
P-glycoprotein
ATPase activity suggesting that
P-glycoprotein
might be the target molecule of these agents.
Cancer Res 1988
Sep
01
PMID:Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. 290 Jun 77
A human T lymphoblastoid CCRF-CEM cell line exhibiting cross resistance to a variety of drugs was selected with increasing doses of actinomycin D. A subline, designated CCRF ACTD400+, was permanently cultured in the presence of 400 ng/ml Actinomycin D for several months. Using a fragment of the human mdr1 cDNA we found high expression of a 5 kb mRNA species which was not detectable in the sensitive parental CCRF-CEM cell line. The extent of the mdr-mRNA expression in resistant cells, however, depended on the presence or absence of actinomycin D in the culture medium: when the inhibitor was omitted, the expression decreased to about 60% after one month. In reverse, the steady state level of the
P-glycoprotein
mRNA increased about 2.5-fold within 72 h after the original dose of the drug was added again. In further experiments we recorded the actinomycin D or adriamycin dose response curves of the variously treated sublines by evaluation of [3H]uridine or [3H]thymidine incorporation, respectively, into acid insoluble material. Consistently, the drug sensitivity of the respective macromolecular synthesis was found to decrease with increasing mdr-mRNA levels.
Biochem Biophys Res Commun 1988
Sep
15
PMID:Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line. 290 35
Multidrug resistance (MDR) refers to a complex phenotype that describes a number of features characterized primarily by resistance to a wide range of structurally unrelated drugs. In this paper we investigated the relationship between drug resistance and resistance to NK-mediated cytotoxicity. Studies with two independently selected multidrug-resistant cell lines indicated that increased drug resistance was associated with both an increased resistance to NK-mediated cytotoxicity and increased levels of membrane
P-glycoprotein
expression. This resistance to cytotoxicity appears to result partly from an alteration in the membrane structure of the target cells inasmuch as there was a reduction in effector:target cell recognition. Resistance to NK-mediated cytotoxicity should be included with the numerous pleiotropic changes associated with the multidrug resistance phenotype.
FASEB J 1988
Sep
PMID:Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity. 304 4
Independent lines of Chinese hamster ovary cells resistant to the antineoplastic drug, daunorubicin, were obtained by clonal isolation in increasing drug concentrations. A single daunorubicin-resistant phenotype typified by reduced cellular drug accumulation was observed. These mutants displayed a complex phenotype of resistance to a variety of unrelated drugs. Such properties are similar to those of membrane-altered colchicine-resistant lines (V. Ling and L.H. Thompson, J. Cell. Physiol., 83: 103-116, 1974). Analysis of the plasma membrane components of the daunorubicin-resistant clones by gel electrophoresis revealed a prominent cell surface glycoprotein with a molecular weight of about 170,000. This component was immunologically cross-reactive with the cell surface
P-glycoprotein
of about the same molecular weight, previously identified in colchicine-resistant cells. Thus, it appears that the mechanism of resistance characterized by
P-glycoprotein
expression could be the basis of many drug-resistant phenotypes.
Cancer Res 1983
Sep
PMID:Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. 613 5
The plasma membranes of hamster, mouse, and human tumor cell lines that display multiple resistance to drugs were examined by gel electrophoresis and immunoblotting. In every case, increased expression of a 170,000-dalton surface antigen was found to be correlated with multidrug resistance. This membrane component is of identical molecular size and shares some immunogenic homology with the previously characterized
P-glycoprotein
of colchicine-resistant Chinese hamster ovary cells. This finding may have application to cancer therapy.
Science 1983
Sep
23
PMID:Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. 613 59
A monoclonal antibody produced by hybridomas obtained from a mouse immunized with drug-resistant cells recognizes certain hamster and human drug-resistant cell lines but not their drug-sensitive parental lines. Preliminary characterization of the antigen indicates that it is a molecule of approximately 180,000 daltons. This molecule may be the
P-glycoprotein
previously associated with a drug-resistance permeability barrier (Riordan JR, Ling V: J Biol Chem 254:12701-12705, 1979).
J Clin Immunol 1984
Sep
PMID:Cells resistant to cytotoxic drugs are recognized by monoclonal antibody. 614 30
Using four cell lines including drug-sensitive K562/Parent cells,
P-glycoprotein
(Pgp)-mediated multidrug resistant (MDR) K562/VCR, K562/ADR and revertant K562/ADR-R cells, two fluorescent agents, Fluo-3 and rhodamine-123 (Rh-123), were compared as indicators in a functional assay of MDR. Cells were incubated with 4 microM Fluo-3 or 1 microM Rh-123 for 45 min and then the intracellular accumulation of the agent was measured using a flow cytometer. Verapamil (20 microM) or cepharanthine (biscoclaurine alkaloid, 10 microM) was added just before the fluorescent agents. Efflux patterns were also studied 60 min after incubation with or without verapamil and cepharanthine. Increased intracellular accumulation and a delayed efflux pattern of Fluo-3 by verapamil and cepharanthine were demonstrated in multidrug resistant K562/VCR and K562/ADR cells, indicating that Fluo-3 is another good indicator of MDR. However, a similar, but lower, increase in uptake and a delayed efflux pattern of Fluo-3 by verapamil and cepharanthine were also demonstrated even in Pgp-non-overexpressed K562/Parent cells. In contrast, accumulation of Rh-123 was not affected by verapamil and cepharanthine. To further study the Pgp dependency of Fluo-3, another cell line, K562/NC16 expressing minimum MDR1 mRNA, was cloned. Increased uptake and a delayed efflux pattern of Fluo-3, but not Rh-123, with verapamil or cepharanthine were again demonstrated in K562/NC16 cells, indicating that intracellular accumulation of Fluo-3 may be non-specifically influenced by verapamil and cepharanthine at very low levels of Pgp-related MDR, while the influx and efflux patterns of Rh-123 may be specifically affected by Pgp overexpression.
Eur J Cancer 1995
Sep
PMID:Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123. 748 25
P-Glycoprotein is an integral membrane protein which mediates the energy-dependent efflux of various antitumor agents from multidrug-resistant cancer cells. Surface plasmon resonance was used for the detection of
P-glycoprotein
after solubilization from drug-resistant and drug-sensitive Chinese hamster ovary cells and for the analysis of its interaction with cyclosporin A, a competitive inhibitor of drug efflux. Detection of
P-glycoprotein
relied on its binding to the monoclonal antibody C219 which was immobilized on a sensor chip. Binding of Zwittergent 3-14-solubilized
P-glycoprotein
to the antibody was concentration-dependent and reflected the relative abundance of
P-glycoprotein
in both cell lines. It was abolished when C219 was omitted or replaced by a rabbit anti-mouse IgG antibody and considerably reduced after precipitation of
P-glycoprotein
with wheat germ agglutinin. Preincubation of solubilized proteins with cyclosporin A increased the amount of protein bound to the antibody by approximately 30%. These results indicate that surface plasmon resonance is well suited to the detection of
P-glycoprotein
from biological samples and shows promise as a tool for the study of its interaction with different drugs.
Anal Biochem 1995
Sep
20
PMID:Molecular study of P-glycoprotein in multidrug resistance using surface plasmon resonance. 750 13
The emergence of multidrug resistance in tumor cells is caused by the expression of
P-glycoprotein
.
P-glycoprotein
has a unique structure formed by two homologous halves, each encoding six putative transmembrane segments and one nucleotide binding fold. This structural arrangement has been conserved in a large number of eukaryotic and prokaryotic membrane transport systems, which together form the ATP binding cassette superfamily. These membrane transporters act on different groups of substrates in different cell types and organisms. The combined molecular analysis of these proteins has shed light on the mechanism by which
P-glycoprotein
acts on structurally unrelated groups of chemotherapeutic drugs and has allowed the identification of the protein domain responsible for the common mechanism of transport and recognition of substrate molecules. The function of
P-glycoprotein
in normal tissues remains intriguing and is discussed in this review.
Curr Opin Nephrol Hypertens 1993
Sep
PMID:Structural and functional aspects of P-glycoproteins and related transport proteins. 752 12
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>